For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant change. These innovative therapies preserve the transthyretin protein, slowing its harmful build-up and reducing the burden